Tablet
Latest AstraZeneca AB Patents:
- Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer
- Combination treatment by administering a recombinant apyrase protein in conjunction with a P2Yinhibitor
- Dry powder formulation for pulmonary delivery and methods of use
- POLQ inhibitors
- ORAL FORMULATION OF A THERAPEUTIC COMPOUND
Description
The file of this patent contains at least one photograph executed in color. Copies of this patent with color photographs will be provided by the Office upon request and payment of the necessary fee.
Claims
The ornamental design for a tablet, as shown and described.
Referenced Cited
U.S. Patent Documents
Other references
| 4439195 | March 27, 1984 | Swanson et al. |
| D377086 | December 31, 1996 | Tortarolo |
| D430285 | August 29, 2000 | Chen et al. |
| D437407 | February 6, 2001 | Burrows |
| D493518 | July 27, 2004 | McAllister et al. |
| D506545 | June 21, 2005 | McAllister et al. |
| 7029699 | April 18, 2006 | Robinson et al. |
| D564086 | March 11, 2008 | Nielsen et al. |
| D601689 | October 6, 2009 | Karolak et al. |
- U.S. Appl. No. 29/356,485, filed Feb. 26, 2010.
- Japanese Publication # 022396, magazine published 2006.
Patent History
Patent number: D685460
Type: Grant
Filed: Feb 26, 2010
Date of Patent: Jul 2, 2013
Assignee: AstraZeneca AB (Sodertalje)
Inventors: Tove Illing (Congleton), Johan Janner (Södertälje), Jonathan Sutch (Nottingham)
Primary Examiner: Ian Simmons
Assistant Examiner: Charles Hanson
Application Number: 29/356,484
Type: Grant
Filed: Feb 26, 2010
Date of Patent: Jul 2, 2013
Assignee: AstraZeneca AB (Sodertalje)
Inventors: Tove Illing (Congleton), Johan Janner (Södertälje), Jonathan Sutch (Nottingham)
Primary Examiner: Ian Simmons
Assistant Examiner: Charles Hanson
Application Number: 29/356,484
Classifications
Current U.S. Class:
Tablet Or Caplet (1) (D24/101)